ECSP12011630A - PHARMACEUTICAL FORMULATION - Google Patents

PHARMACEUTICAL FORMULATION

Info

Publication number
ECSP12011630A
ECSP12011630A ECSP12011630A ECSP12011630A EC SP12011630 A ECSP12011630 A EC SP12011630A EC SP12011630 A ECSP12011630 A EC SP12011630A EC SP12011630 A ECSP12011630 A EC SP12011630A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Jean-Pierre Burnouf
Tsiala Benard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority to ECSP12011630 priority Critical patent/ECSP12011630A/en
Publication of ECSP12011630A publication Critical patent/ECSP12011630A/en

Links

ECSP12011630 2012-01-27 2012-01-27 PHARMACEUTICAL FORMULATION ECSP12011630A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP12011630 ECSP12011630A (en) 2012-01-27 2012-01-27 PHARMACEUTICAL FORMULATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP12011630 ECSP12011630A (en) 2012-01-27 2012-01-27 PHARMACEUTICAL FORMULATION

Publications (1)

Publication Number Publication Date
ECSP12011630A true ECSP12011630A (en) 2012-02-29

Family

ID=52449853

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011630 ECSP12011630A (en) 2012-01-27 2012-01-27 PHARMACEUTICAL FORMULATION

Country Status (1)

Country Link
EC (1) ECSP12011630A (en)

Similar Documents

Publication Publication Date Title
DK3181128T3 (en) NILOTINIB PHARMACEUTICAL COMPOSITION
HRP20211423T4 (en) ENZALUTAMIDE FORMULATIONS
DK2858671T3 (en) antibody Formulation
DK2890397T3 (en) ANTIPROLACTINRECEPTOR antibody formulation
PT2854768T (en) PEMETREXED PHARMACEUTICAL COMPOSITIONS
CO6940426A2 (en) Pharmaceutical formulations
DK2897594T3 (en) PHARMACEUTICAL COMPOSITION
DK2502622T3 (en) Pharmaceutical formulation comprising inositol
BR112014000015A2 (en) formulation
DK2868318T4 (en) INJECTIBLE FORMULATION
CL2014003283A1 (en) Pharmaceutical formulation
DK2815752T3 (en) ORAL PHARMACEUTICAL COMPOSITION
DK2877155T3 (en) OPIOID FORMULATIONS
EP2883547A4 (en) DRUG
DK2854765T3 (en) PHARMACEUTICAL PEMETREXED SOLUTION
EP2770828A4 (en) FORMULATION
ZA201405925B (en) Pharmaceutical formulation having improved stability
PT2908835T (en) STABLE FORMULATIONS
CO7091176A2 (en) Pharmaceutical diagnosis
DK3473255T3 (en) PHARMACEUTICAL FORMULATION INCLUDING CICLESONIDE
DK3003401T3 (en) PHARMACEUTICAL PREPARATION
BR112015002646A2 (en) compound and pharmaceutical composition
PL2908836T3 (en) Pharmaceutical formulation containing curcumin
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
BR302012003979S1 (en) PHARMACEUTICAL CONFIGURATION